Takeda Pharmaceutical (NYSE:TAK) Insider Sells 165,393 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Stewart Plump sold 165,393 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $2,828,220.30. Following the sale, the insider directly owned 766,569 shares of the company’s stock, valued at approximately $13,108,329.90. This represents a 17.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Trading Down 0.3%

Shares of Takeda Pharmaceutical stock traded down $0.06 on Wednesday, reaching $17.42. 2,004,364 shares of the company were exchanged, compared to its average volume of 4,402,927. The stock has a fifty day moving average price of $16.49 and a 200-day moving average price of $17.13. The firm has a market capitalization of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. Takeda Pharmaceutical Co. has a fifty-two week low of $12.99 and a fifty-two week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The business had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. On average, analysts expect that Takeda Pharmaceutical Co. will post 3.01 EPS for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the stock. Valeo Financial Advisors LLC acquired a new position in shares of Takeda Pharmaceutical in the second quarter worth $163,000. GAMMA Investing LLC boosted its position in Takeda Pharmaceutical by 10.7% during the second quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock valued at $222,000 after purchasing an additional 1,338 shares during the last quarter. Versant Capital Management Inc grew its stake in Takeda Pharmaceutical by 10.8% in the second quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock valued at $684,000 after purchasing an additional 4,169 shares in the last quarter. Parallel Advisors LLC grew its stake in Takeda Pharmaceutical by 10.5% in the first quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock valued at $457,000 after purchasing an additional 2,343 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its position in Takeda Pharmaceutical by 9.6% in the 1st quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock worth $559,000 after purchasing an additional 2,640 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on TAK. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.